Dorian LPG
LPG
YETI Holdings
YETI
Workday
WDAY
Collegium Pharmaceutical
COLL
LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
US Stock MarketDetailed Quotes
SPRY ARS Pharmaceuticals
- 11.530
- +0.090+0.79%
Close Mar 18 16:00 ET
- 11.300
- -0.230-1.99%
Pre 06:14 ET
1.12BMarket Cap-23.06P/E (TTM)
11.757High11.070Low778.09KVolume11.300Open11.440Pre Close8.97MTurnover1.67%Turnover RatioLossP/E (Static)97.19MShares18.51052wk High5.58P/B536.38MFloat Cap7.55052wk Low--Dividend TTM46.52MShs Float63.410Historical High--Div YieldTTM6.01%Amplitude2.550Historical Low11.532Avg Price1Lot Size
ARS Pharmaceuticals Stock Forum
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) is a biopharmaceutical company focused on developing and commercializing neffy, a needle-free intranasal epinephrine spray designed for emergency treatment of Type I allergic reactions, including anaphylaxis. Below is an analysis of SPRY stock based on available data as of March 17, 2025:
### Company Overview
- Product: Neffy is the first FDA-approved needle-free epinephrine delivery system, offering an al...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If y...
just
ARS Pharmaceuticals Announces FDA Approval of Neffy® 1 Mg (Epinephrine Nasal Spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
Positive
First FDA-approved needle-free epinephrine nasal spray
Rapid inclusion on Express Scripts Commercial National Formularies (9 weeks post-launch)
Access to millions of commercially insured patients
Superior product features: 30-month shelf-life, high temperature tolerance (122°F)
Negative
to patients weighing ≥30 kg (66 lbs.)
Current...
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
Agreement leverages ALK's global footprint in developing and commercializing innovative allergy products
ARS Pharma to receive an upfront cash payment of $145 million, with total deal consideration of up to $465 million plus double-digit royalties on net sales
ARS Pharma retains all U.S. rig...
No comment yet